ERBB2 and breast carcinoma: A166 has promising antitumour activity in HER2-positive breast cancer patients at 4.8 mg/kg with manageable toxicity, which led to governmental approval of a pivotal phase II registration trial in HER2-positive patients who have progressed on at least two prior lines of anti-HER2 therapies.